Webinar: ACR/CHEST ILD Guidelines in Practice| Video: COVID in the Rear View

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Deucravacitinib Promising for PsA

  |  

References

  1. A study to determine the efficacy and safety of deucravacitinib compared with placebo in participants with active psoriatic arthritis (PsA) who are naïve to biologic disease-modifying anti-rheumatic drugs [NCT04908202]. ClinicalTrials.gov. 2024 Sep 27.
  2. A study to determine the efficacy and safety of deucravacitinib compared with placebo in participants with active psoriatic arthritis (PsA) who are naïve to biologic disease modifying anti-rheumatic drugs or had previously received TNFα inhibitor treatment [NCT04908189]. ClinicalTrials.gov. 2024 Nov 1.
  3. Highlights of prescribing information: Sotyktu (deucravacitinib). 2022 Sep 9.
  4. Bristol Myers Squibb announces positive topline results from two pivotal phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with psoriatic arthritis [news release]. Bristol Myers Squibb. 2024 Dec 23.
  5. Sotyktu (deucravacitinib) tablets new drug application approval letter. U.S. Food & Drug Administration. 2022 Sep 9.

Related Articles

    The Heterogeneity of Psoriatic Arthritis

    SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.

    Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024

    Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…